Returns | 1W : 0.8% , 1M : -0%,1Y : 8.5% |
LT :   |
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
GLAXOSMITHKLINE PHARMACEUTICALS LTD | 0.8% | -0% | 8.5% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 2% | 4.1% | 55.6% |
DR REDDYS LABORATORIES LTD | -0.8% | -0.5% | 45.1% |
DIVIS LABORATORIES LTD | 0.9% | 1.3% | 60.4% |
CIPLA LTD | 2.9% | 0.8% | 87.3% |
BIOCON LTD | 2% | 4.8% | 32.2% |
AUROBINDO PHARMA LTD | 2.9% | -3.8% | 68.2% |
LUPIN LTD | 4.7% | 6.7% | 54.3% |
TORRENT PHARMACEUTICALS LTD | -0.3% | -2.5% | 12.2% |
Ratio | Value |
---|---|
P/E P/B P/S |
225.71
P/E Calculated based on EPS of 6.5
[ Mar2020 - Standalone Results ] 13.51
P/B Calculated based on Book Value of 108.62
[ Mar2020 - Standalone Results ] 8.06
P/S Calculated based on Revenues of 3085.31 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
58% 20% 15% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |